Reuters logo
8 months ago
BRIEF-Bluebird Bio announces treatment of first patient with thalassemia drug
December 14, 2016 / 1:30 PM / 8 months ago

BRIEF-Bluebird Bio announces treatment of first patient with thalassemia drug

Dec 14 (Reuters) - Bluebird Bio Inc

* Bluebird Bio Inc says also moving forward with plans to initiate northstar-3 (hgb-212), a phase 3 trial of lentiglobin drug product

* Bluebird Bio Inc says this study will also be conducted under new manufacturing process, and is expected to begin enrolling patients in 2017

* Bluebird bio announces first patient treated with lentiglobintm drug product in northstar-2 (hgb-207) phase 3 trial of patients with transfusion-dependent -thalassemia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below